GEN Exclusives

More »

GEN News Highlights

More »
Nov 7, 2006

SRI International Recipient of $56.9M from the NIAID

  • SRI International has been awarded a $56.9-million contract from the NIAID to provide preclinical services for the development of drugs and antibodies for anti-infective therapeutics.

    SRI will support the development of treatments for avian flu, SARS, West Nile virus, hepatitis, and biodefense pathogens and toxins for five years. The company will perform medicinal chemistry, custom drug synthesis, formulation, analytical chemistry, clinical manufacturing, microbiology and virology screening, pharmacokinetics, safety testing, and preparation of IND applications to the FDA.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?